Investment Rating - The investment rating for the company is "Outperform" (maintained) [1][3] Core Views - The company has accelerated the overseas registration of raw materials and the implementation of industry standards in the new materials sector, which enhances competitive barriers [1][4] - In 2025, the company reported a revenue of 553 million yuan, a year-on-year increase of 2.87%, and a net profit attributable to the parent company of 132 million yuan, up 6.32% year-on-year [3][4] - The company is focusing on both domestic and international markets, with a strategy to maintain stable revenue growth through the commercialization of new raw materials and the optimization of internal management [4][5] Financial Summary - Revenue projections for 2025-2027 are 553 million yuan (2025), 635 million yuan (2026), and 717 million yuan (2027), with corresponding net profits of 132 million yuan, 153 million yuan, and 174 million yuan [6][8] - The company's gross margin is expected to remain stable around 43.9% in 2025, with a net margin of 23.8% [6][9] - The earnings per share (EPS) forecast for 2025-2027 is 0.31 yuan, 0.36 yuan, and 0.41 yuan, respectively, with a price-to-earnings (P/E) ratio of 33.6, 28.8, and 25.4 [6][8]
森萱医药（920946）：北交所信息更新：原料药海外注册加速，新材料行业标准落地提升壁垒